Table 3.
Comparison of our model-based predictions of cure rates with observational data.
| Regimen | % cured at: | Ref. | |||
|---|---|---|---|---|---|
| 3 months | 4 months | 5 months | |||
| Our model BALB/c, Beijing, HDIT | 2 RpZHE/1,2,3 RpHa | 62% | 97% | 100% | |
| 2 RZME/1,2,3 RMa | 60% | 97% | 100% | ||
| 2 RZMH/1,2,3 RMHa | 2% | 29% | 81% | ||
| Model 1 BALB/c, H37Rv, HDA | 2 RpZM/1,2 RpM | 100% | 22 | ||
| 3,4,5 RZM | 75% | 100% | 100% | 5 | |
| 2 RZM/1,2,3 RM | 83% | 100% | 100% | 5 | |
| 2 RZM/2,3 RM | 95% | 100% | 23 | ||
| Model 2 BALB/c, H37Rv, LDA | 2 RZME/1 RM | 80% | 12 | ||
| 2 RZMH/1 RMH | 27% | 12 | |||
| Model 3 BALB/c, Erdman, HDA | 2 RZM/2 RM | 84% | 13 | ||
| Model 4 BALB/c, Erdman, LDA | 3 RZME | 100% | 12 | ||
| 3 RZMH | 93% | 12 | |||
| 2 RZM/1 RM, 2 RM | 100% | 95% | 13 | ||
| Model 5 C3HeB/FeJb, H37Rv, LDA | 2 RZME/1 RM | 80% | 12 | ||
| 2 RZMH/1 RMH | 80% | 12 | |||
| Model 6 C3HeB/FeJb, Erdman, LDA | 3 RZME | 40% | 12 | ||
| 3 RZMH | 0% | 12 | |||
aPredicted cure for 3,4 and 5 months of treatment is shown as estimated in Fig. 3, bC3HeB/FeJ mice can develop cavitating lesions that more closely resemble human disease, Abbreviations for route of infection: HDIT = high dose intratracheally, HDA = high dose aerosol, LDA = low dose aerosol, R = rifampicin, Rp = rifapentine, Z = pyrazinamide, M = moxifloxacin, H = isoniazid, E = Ethambutol.